These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28418843)

  • 1. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer.
    Deng X; Apple S; Zhao H; Song J; Lee M; Luo W; Wu X; Chung D; Pietras RJ; Chang HR
    Oncotarget; 2017 Jun; 8(24):38294-38308. PubMed ID: 28418843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 as a promising chemoresistance biomarker associated with the CD44
    Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
    Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard chemotherapy impacts on in vitro cellular heterogeneity in spheroids enriched with cancer stem cells (CSCs) derived from triple-negative breast cancer cell line.
    Moreira MP; Franco EP; Barros BAF; Anjos BRD; Almada DG; Barbosa INT; Braga LDC; Cassali GD; Silva LM
    Biochem Biophys Res Commun; 2024 Nov; 734():150765. PubMed ID: 39357337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
    Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
    Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of human breast cancer CD44
    Qiao X; Zhang Y; Sun L; Ma Q; Yang J; Ai L; Xue J; Chen G; Zhang H; Ji C; Gu X; Lei H; Yang Y; Liu C
    Elife; 2021 Jul; 10():. PubMed ID: 34318746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer.
    Chang SJ; Ou-Yang F; Tu HP; Lin CH; Huang SH; Kostoro J; Hou MF; Chai CY; Kwan AL
    Hum Pathol; 2016 Feb; 48():48-55. PubMed ID: 26772398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
    Chen Y; Song J; Jiang Y; Yu C; Ma Z
    Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
    Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
    Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD24 is a Potential Biomarker for Prognosis in Human Breast Carcinoma.
    Jing X; Cui X; Liang H; Hao C; Yang Z; Li X; Yang X; Han C
    Cell Physiol Biochem; 2018; 48(1):111-119. PubMed ID: 30001552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
    Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
    Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer.
    Chan SH; Tsai KW; Chiu SY; Kuo WH; Chen HY; Jiang SS; Chang KJ; Hung WC; Wang LH
    Mol Cancer Ther; 2019 Jan; 18(1):147-161. PubMed ID: 30381446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer.
    Murthy D; Dutta D; Attri KS; Samanta T; Yang S; Jung KH; Latario SG; Putluri V; Huang S; Putluri N; Park JH; Kaipparettu BA
    Cancer Lett; 2024 Apr; 587():216724. PubMed ID: 38373689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors.
    Uchôa Dde M; Graudenz MS; Callegari-Jacques SM; Hartmann CR; Ferreira BP; Fitarelli-Kiehl M; Edelweiss MI
    Pathol Res Pract; 2014 Jul; 210(7):432-9. PubMed ID: 24726267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
    Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
    Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New 3-alkylpyridine marine alkaloid analogues as promising antitumor agents against the CD44
    de Lima AB; Barbosa CS; Gonçalves AMMN; Santos FVD; Viana GHR; Varotti FP; Silva LM
    Chem Biol Drug Des; 2017 Jul; 90(1):5-11. PubMed ID: 27995747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocan as a prognostic biomarker of triple-negative breast cancer.
    Sagara A; Igarashi K; Otsuka M; Kodama A; Yamashita M; Sugiura R; Karasawa T; Arakawa K; Narita M; Kuzumaki N; Narita M; Kato Y
    Breast Cancer Res Treat; 2017 Jan; 161(2):269-278. PubMed ID: 27888420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.